1. "2020"
Formats
  1. Journal Article (2337)
  2. Meeting Abstract (1901)
  3. Review (493)
  4. Editorial (342)
  5. Correspondence (121)
  6. Guidelines (114)
  7. Book Section (99)
  8. Research Letter (95)
  9. Miscellaneous (61)
  10. Conference Paper (33)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2560)
  2. Solid Tumor Oncology Division (1535)
  3. GSK Faculty (1257)
  4. Sloan Kettering Institute Postdocs (1240)
  5. Hematologic Malignancies, Division of (936)
  6. Survivorship Research (930)

More Groups

People
  1. Jorge Reis-Filho (93)
  2. Miguel-Angel Perales (93)
  3. Sergio Giralt (91)
  4. Alexander Drilon (81)
  5. Britta Weigelt (76)
  6. Nadeem Abu-Rustum (71)

More People

Years
  1. 2020 (5598)
Publications
  1. Journal of Clinical Oncology (500)
  2. Blood (212)
  3. Cancer Research (185)
  4. Annals of Oncology (152)
  5. International Journal of Radiation Oncology, Biology, Physics (129)
  6. Laboratory Investigation (116)

More Publications

Publishers
  1. Elsevier Inc. (714)
  2. American Society of Clinical Oncology (548)
  3. Nature Publishing Group (385)
  4. American Association for Cancer Research (357)
  5. Oxford University Press (356)
  6. Springer (342)

More Publishers

Results (5598)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Tran, B.; Horvath, L.; Dorff, T.; Rettig, M.; Lolkema, M. P.; Machiels, J. P.; Rottey, S.; Autio, K.; Greil, R.; Adra, N.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
    Meeting Abstract

    Leyvraz, S.; Yang, J. C. H.; Casali, P. G.; Castro, G.; Kim, E. S.; Lassen, U. N.; Lopez-Rios, F.; Penault-Llorca, F.; Pappo, A.; Rudzinski, E. R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
    Meeting Abstract

    Schuler, M.; Tabernero, J.; Massard, C.; Vasudeva Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Lu-Emerson, C.; Hargrave, D.; Garcia-Corbacho, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
    Meeting Abstract

    Italiano, A.; Hong, D. S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U. N.; Vassal, G.; Kummar, S.; van Tilburg, C. M.; Keating, K.; Reeves, J. A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    Drilon, A.; Paz-Ares, L.; Doebele, R. C.; Farago, A. F.; Liu, S. V.; Chawla, S. P.; Tosi, D.; Blakely, C. M.; Krauss, J. C.; Bazhenova, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours
    Meeting Abstract

    Paik, P. K.; Xiong, W.; Hietala, S. F.; Nyberg, J.; Papasouliotis, O.; Anziano, R.; Berghoff, K.; Johne, A.; Girard, P.; Strotmann, R.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
    Meeting Abstract

    Conley, A. P.; Demetri, G. D.; Doebele, R. C.; Drilon, A.; Paz-Ares, L.; Cassier, P.; Siena, S.; Ahn, M. J.; Buchschacher, G. L. Jr; Seto, T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
    Meeting Abstract

    Gouda, M. A.; Sherman, E. J.; Gilcrease, G. W.; Vaishampayan, U. N.; Parikh, A.; Feun, L.; Kummar, S.; Huang, H.; Zhang, C.; Severson, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy
    Meeting Abstract

    Liu, S. V.; De Braud, F.; Drilon, A.; Doebele, R. C.; Patel, M. R.; Cho, B. C.; Ahn, M. J.; Chiu, C. H.; Farago, A. F.; Goto, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
    Meeting Abstract

    Ku, G.; Bendell, J. C.; Tolcher, A. W.; Hurvitz, S. A.; Krishnamurthy, A.; El-Khoueiry, A. B.; Patnaik, A.; Shroff, R. T.; Noonan, A.; Hahn, N. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save